Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

The requested reference [80ab663485a5dcb2c5b93d334a108fbf6752c8c5] no longer exists in our database. It has been replaced by the current reference: [cab09fe4f737172193600c60caad87a49a188e01]

Authors Oyster Point Pharma, Inc. -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
Links ClinicalTrials.gov
This was a Phase 2, single‐center, randomized, masked (including all subjects, investigators, and study site personnel), placebo‐controlled study designed to evaluate the safety and efficacy of OC‐01 (varenicline) nasal spray in stimulating goblet cell and Meibomian gland function in in adult subjects with DED. Approximately 45 subjects at least 18 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria were planned to be randomized to receive a single application of 0.2% (1.2 mg/mL) OC‐01 or placebo
Epistemonikos ID: 81b5375ec0e85a3848f9699ad58b3e5d5413e242
First added on: Dec 20, 2022